Alimera End Period Cash Flow vs Ev To Free Cash Flow Analysis

ALIM Stock

USD 2.89 0.12 3.99%

Alimera Sciences financial indicator trend analysis is way more than just evaluating Alimera Sciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alimera Sciences is a good investment. Please check the relationship between Alimera Sciences End Period Cash Flow and its Ev To Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.

End Period Cash Flow vs Ev To Free Cash Flow

End Period Cash Flow vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alimera Sciences End Period Cash Flow account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Alimera Sciences' End Period Cash Flow and Ev To Free Cash Flow is 0.42. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Alimera Sciences, assuming nothing else is changed. The correlation between historical values of Alimera Sciences' End Period Cash Flow and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Alimera Sciences are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of End Period Cash Flow i.e., Alimera Sciences' End Period Cash Flow and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.42

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

End Period Cash Flow

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Alimera Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alimera Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.At this time, Alimera Sciences' Tax Provision is very stable compared to the past year. As of the 12th of June 2024, Issuance Of Capital Stock is likely to grow to about 85.1 M, while Sales General And Administrative To Revenue is likely to drop 0.22.

	2021	2022	2023	2024 (projected)
Interest Expense	5.4M	5.9M	10.2M	10.7M
Depreciation And Amortization	2.6M	2.7M	8.7M	9.2M

Interest Expense Depreciation And Amortization

Alimera Sciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.76	0.88	0.18	0.73	0.51	-0.3	0.44	-0.48	0.27	0.15	0.94	0.06	0.16	0.68	-0.13	0.86	0.7	0.19	0.34	0.38	0.56	0.71	0.58	-0.11	0.32
Short Long Term Debt Total	0.76		0.75	0.38	0.32	0.84	-0.64	0.86	-0.85	0.77	-0.34	0.82	-0.07	-0.34	0.93	-0.21	0.8	0.67	0.56	0.58	0.74	0.69	0.82	0.23	0.06	0.13
Other Current Liab	0.88	0.75		0.25	0.58	0.55	-0.41	0.59	-0.5	0.33	-0.14	0.93	-0.02	-0.13	0.77	-0.38	0.95	0.63	0.26	0.37	0.42	0.5	0.76	0.28	-0.06	0.1
Total Current Liabilities	0.18	0.38	0.25		0.03	0.55	-0.34	0.35	-0.38	0.46	-0.19	0.21	0.0	-0.2	0.33	-0.17	0.21	-0.16	0.17	0.28	0.38	0.28	0.32	0.04	0.92	-0.08
Total Stockholder Equity	0.73	0.32	0.58	0.03		0.05	0.01	-0.07	-0.3	-0.13	0.54	0.57	0.14	0.55	0.19	0.28	0.47	0.1	-0.16	0.15	0.31	-0.05	0.26	0.72	-0.1	0.56
Property Plant And Equipment Net	0.51	0.84	0.55	0.55	0.05		-0.63	0.79	-0.74	0.81	-0.43	0.59	-0.1	-0.42	0.8	-0.44	0.63	0.49	0.6	0.67	0.64	0.64	0.9	0.07	0.3	-0.2
Current Deferred Revenue	-0.3	-0.64	-0.41	-0.34	0.01	-0.63		-0.63	0.69	-0.61	0.37	-0.38	0.06	0.37	-0.51	0.13	-0.37	-0.33	-0.83	-0.75	-0.6	-0.45	-0.49	0.03	-0.2	0.0
Net Debt	0.44	0.86	0.59	0.35	-0.07	0.79	-0.63		-0.77	0.75	-0.77	0.65	-0.1	-0.77	0.94	-0.35	0.72	0.57	0.56	0.49	0.65	0.61	0.75	-0.3	0.08	-0.05
Retained Earnings	-0.48	-0.85	-0.5	-0.38	-0.3	-0.74	0.69	-0.77		-0.77	0.37	-0.53	0.08	0.37	-0.75	-0.05	-0.53	-0.27	-0.57	-0.67	-0.92	-0.34	-0.61	-0.11	-0.14	-0.24
Accounts Payable	0.27	0.77	0.33	0.46	-0.13	0.81	-0.61	0.75	-0.77		-0.46	0.33	-0.13	-0.47	0.7	-0.26	0.38	0.37	0.63	0.61	0.8	0.64	0.6	0.05	0.17	-0.13
Cash	0.15	-0.34	-0.14	-0.19	0.54	-0.43	0.37	-0.77	0.37	-0.46		-0.16	0.11	1.0	-0.57	0.36	-0.3	-0.21	-0.37	-0.21	-0.32	-0.29	-0.35	0.81	-0.09	0.25
Non Current Assets Total	0.94	0.82	0.93	0.21	0.57	0.59	-0.38	0.65	-0.53	0.33	-0.16		0.04	-0.15	0.83	-0.24	0.97	0.75	0.24	0.35	0.41	0.61	0.79	0.29	-0.09	0.26
Non Currrent Assets Other	0.06	-0.07	-0.02	0.0	0.14	-0.1	0.06	-0.1	0.08	-0.13	0.11	0.04		0.11	-0.06	0.54	0.02	-0.04	0.02	-0.23	-0.07	-0.06	-0.01	0.07	0.03	0.6
Cash And Short Term Investments	0.16	-0.34	-0.13	-0.2	0.55	-0.42	0.37	-0.77	0.37	-0.47	1.0	-0.15	0.11		-0.56	0.35	-0.29	-0.21	-0.37	-0.22	-0.32	-0.29	-0.35	0.81	-0.09	0.25
Net Receivables	0.68	0.93	0.77	0.33	0.19	0.8	-0.51	0.94	-0.75	0.7	-0.57	0.83	-0.06	-0.56		-0.35	0.87	0.7	0.46	0.44	0.63	0.67	0.85	-0.03	0.0	0.03
Common Stock Total Equity	-0.13	-0.21	-0.38	-0.17	0.28	-0.44	0.13	-0.35	-0.05	-0.26	0.36	-0.24	0.54	0.35	-0.35		-0.38	-0.39	-0.18	-0.25	0.06	-0.4	-0.49	0.22	-0.03	0.86
Common Stock Shares Outstanding	0.86	0.8	0.95	0.21	0.47	0.63	-0.37	0.72	-0.53	0.38	-0.3	0.97	0.02	-0.29	0.87	-0.38		0.73	0.26	0.37	0.43	0.58	0.84	0.13	-0.11	0.12
Non Current Liabilities Total	0.7	0.67	0.63	-0.16	0.1	0.49	-0.33	0.57	-0.27	0.37	-0.21	0.75	-0.04	-0.21	0.7	-0.39	0.73		0.37	0.27	0.13	0.8	0.67	0.17	-0.43	-0.03
Inventory	0.19	0.56	0.26	0.17	-0.16	0.6	-0.83	0.56	-0.57	0.63	-0.37	0.24	0.02	-0.37	0.46	-0.18	0.26	0.37		0.78	0.52	0.47	0.48	-0.01	0.01	-0.11
Other Current Assets	0.34	0.58	0.37	0.28	0.15	0.67	-0.75	0.49	-0.67	0.61	-0.21	0.35	-0.23	-0.22	0.44	-0.25	0.37	0.27	0.78		0.71	0.44	0.57	0.19	0.08	-0.08
Other Stockholder Equity	0.38	0.74	0.42	0.38	0.31	0.64	-0.6	0.65	-0.92	0.8	-0.32	0.41	-0.07	-0.32	0.63	0.06	0.43	0.13	0.52	0.71		0.35	0.51	0.18	0.12	0.26
Total Liab	0.56	0.69	0.5	0.28	-0.05	0.64	-0.45	0.61	-0.34	0.64	-0.29	0.61	-0.06	-0.29	0.67	-0.4	0.58	0.8	0.47	0.44	0.35		0.64	0.21	-0.02	-0.07
Property Plant And Equipment Gross	0.71	0.82	0.76	0.32	0.26	0.9	-0.49	0.75	-0.61	0.6	-0.35	0.79	-0.01	-0.35	0.85	-0.49	0.84	0.67	0.48	0.57	0.51	0.64		0.13	0.02	-0.11
Total Current Assets	0.58	0.23	0.28	0.04	0.72	0.07	0.03	-0.3	-0.11	0.05	0.81	0.29	0.07	0.81	-0.03	0.22	0.13	0.17	-0.01	0.19	0.18	0.21	0.13		-0.09	0.33
Short Term Debt	-0.11	0.06	-0.06	0.92	-0.1	0.3	-0.2	0.08	-0.14	0.17	-0.09	-0.09	0.03	-0.09	0.0	-0.03	-0.11	-0.43	0.01	0.08	0.12	-0.02	0.02	-0.09		-0.1
Common Stock	0.32	0.13	0.1	-0.08	0.56	-0.2	0.0	-0.05	-0.24	-0.13	0.25	0.26	0.6	0.25	0.03	0.86	0.12	-0.03	-0.11	-0.08	0.26	-0.07	-0.11	0.33	-0.1

Click cells to compare fundamentals

Alimera Sciences Account Relationship Matchups

Alimera Sciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	50.3M	50.9M	58.5M	42.6M	153.5M	161.2M
Short Long Term Debt Total	39.0M	44.6M	43.6M	44.3M	67.4M	70.8M
Other Current Liab	4.7M	3.2M	3.4M	4.0M	12.8M	13.5M
Total Current Liabilities	12.0M	12.3M	12.6M	39.7M	21.9M	14.3M
Total Stockholder Equity	(4.4M)	(8.0M)	(2.6M)	(20.8M)	46.2M	48.5M
Property Plant And Equipment Net	2.0M	2.4M	4.5M	3.9M	3.6M	3.8M
Net Debt	29.6M	33.4M	27.1M	39.1M	55.3M	58.1M
Retained Earnings	(387.6M)	(392.9M)	(397.3M)	(415.4M)	(418.5M)	(439.4M)
Accounts Payable	7.1M	7.5M	8.7M	10.1M	8.3M	5.0M
Cash	9.4M	11.2M	16.5M	5.3M	12.1M	19.3M
Non Current Assets Total	17.6M	15.9M	16.4M	13.2M	101.1M	106.2M
Non Currrent Assets Other	(16.8M)	(15.2M)	833K	183K	52K	54.6K
Cash And Short Term Investments	9.4M	11.2M	16.5M	5.3M	12.1M	20.5M
Net Receivables	19.3M	17.2M	19.1M	19.6M	34.5M	36.3M
Common Stock Total Equity	691K	701K	50K	57K	65.6K	62.3K
Common Stock Shares Outstanding	4.8M	5.1M	6.6M	7.0M	25.6M	26.8M
Liabilities And Stockholders Equity	50.3M	50.9M	58.5M	42.6M	153.5M	161.2M
Non Current Liabilities Total	42.7M	46.5M	48.5M	23.7M	85.4M	89.7M
Inventory	1.4M	2.7M	2.7M	1.6M	1.9M	1.7M
Other Current Assets	2.6M	3.7M	3.8M	2.9M	3.9M	2.5M
Other Stockholder Equity	353.8M	366.2M	377.2M	378.2M	458.6M	286.4M
Total Liab	54.8M	58.8M	61.1M	63.5M	107.4M	58.0M
Property Plant And Equipment Gross	2.0M	2.4M	7.9M	3.9M	8.0M	8.4M
Total Current Assets	32.7M	34.9M	42.2M	29.4M	52.4M	42.4M
Accumulated Other Comprehensive Income	(1.1M)	(553K)	(1.8M)	(3.0M)	1.7M	1.8M
Short Term Debt	255K	1.7M	489K	25.6M	828K	786.6K
Common Stock	50K	57K	69K	70K	524K	329.8K
Other Liab	3.0M	3.1M	3.6M	2.7M	2.4M	2.3M
Long Term Debt	38.7M	42.4M	43.1M	18.7M	64.5M	67.7M
Property Plant Equipment	1.4M	2.0M	1.6M	4.5M	5.2M	5.4M
Net Tangible Assets	(27.6M)	(49.5M)	(39.5M)	(29.1M)	(26.2M)	(27.5M)
Other Assets	1.2M	734K	1.5M	970K	1.1M	1.2M
Good Will	18.7M	16.7M	14.8M	12.8M	14.8M	14.4M
Retained Earnings Total Equity	(399.1M)	(377.1M)	(387.6M)	(392.9M)	(353.6M)	(371.3M)
Long Term Debt Total	34.6M	38.2M	38.7M	42.4M	48.8M	51.2M
Capital Surpluse	341.6M	346.1M	350.1M	365.8M	420.7M	335.8M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Alimera Sciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

Additional Information and Resources on Investing in Alimera Stock

When determining whether Alimera Sciences is a strong investment it is important to analyze Alimera Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alimera Sciences' future performance. For an informed investment choice regarding Alimera Stock, refer to the following important reports:

How To Invest In Alimera

Details

Is Alimera Stock a good investment?

Details

What is Alimera Sciences' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.25)

Revenue Per Share

2.413

Quarterly Revenue Growth

0.699

Return On Assets

(0.01)

Return On Equity

(1.97)

The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alimera End Period Cash Flow vs Ev To Free Cash Flow Analysis

End Period Cash Flow vs Ev To Free Cash Flow

End Period Cash Flow vs Ev To Free Cash Flow Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Ev To Free Cash Flow

Alimera Sciences fundamental ratios Correlations

Alimera Sciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alimera Sciences fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Additional Information and Resources on Investing in Alimera Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock Shares Outstanding	+ 0.97	Non Current Assets Total
Common Stock Shares Outstanding	+ 0.95	Other Current Liab
Non Current Assets Total	+ 0.94	Total Assets
Net Receivables	+ 0.94	Net Debt
Net Receivables	+ 0.93	Short Long Term Debt Total

Other Stockholder Equity	- 0.92	Retained Earnings
Retained Earnings	- 0.85	Short Long Term Debt Total
Inventory	- 0.83	Current Deferred Revenue
Accounts Payable	- 0.77	Retained Earnings
Cash And Short Term Investments	- 0.77	Net Debt
Cash	- 0.77	Net Debt